Leon W M M Terstappen
Overview
Explore the profile of Leon W M M Terstappen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
9435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dathathri E, Peters Y, Andreoli D, Bruins M, Kraan J, Terstappen L, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075569
Metastatic prostate cancer (mPCa) is marked by heterogeneity and therapy resistance, which arise from prolonged therapy regimens. This heterogeneity is reflected in various morphologic and genetic characteristics, biomarker expression, and...
2.
Cieslik S, Zafra A, Driemel C, Sudarsanam M, Cieslik J, Flugen G, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):9.
PMID: 39773651
Background: Circulating tumour cells (CTCs) and tumour-derived extracellular vesicles (tdEVs) have great potential for monitoring therapy response and early detection of tumour relapse, facilitating personalized adjuvant therapeutic strategies. However, their...
3.
Liu P, He S, Mentink A, Hart P, Wu Y, Terstappen L, et al.
FEBS Lett
. 2025 Jan;
599(5):724-738.
PMID: 39743435
Detecting circulating tumor cells (CTCs) is challenging due to their low presence and heterogeneity. Traditional methods using EpCAM-based separation struggle with CTCs that have undergone epithelial-mesenchymal transition, as this results...
4.
He S, Liu P, Wu Y, Agerbaek M, Salanti A, Terstappen L, et al.
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337304
Circulating tumor cells (CTCs) are detected in approximately 30% of metastatic non-small-cell lung cancer (NSCLC) cases using the CellSearch system, which relies on EpCAM immunomagnetic enrichment and Cytokeratin detection. This...
5.
Stoecklein N, Oles J, Franken A, Neubauer H, Terstappen L, Neves R
Med Genet
. 2024 Jun;
35(4):237-250.
PMID: 38835741
This narrative review aims to provide a comprehensive overview of the current state of circulating tumor cell (CTC) analysis and its clinical significance in patients with epithelial cancers. The review...
6.
Abali F, Schasfoort R, Nijland S, Wittenberns J, Tibbe A, den Hartog M, et al.
Sci Rep
. 2024 Apr;
14(1):9457.
PMID: 38658627
Increased use of therapeutic monoclonal antibodies and the relatively high manufacturing costs fuel the need for more efficient production methods. Here we introduce a novel, fast, robust, and safe isolation...
7.
Booijink R, Terstappen L, Dathathri E, Isebia K, Kraan J, Martens J, et al.
Mol Oncol
. 2024 Apr;
PMID: 38634185
In prostate cancer (PCa), cancer-associated fibroblasts (CAFs) promote tumor progression, drug resistance, and metastasis. Although circulating tumor cells are studied as prognostic and diagnostic markers, little is known about other...
8.
Nanou A, Stoecklein N, Doerr D, Driemel C, Terstappen L, Coumans F
PNAS Nexus
. 2024 Feb;
3(2):pgae048.
PMID: 38371418
Circulating tumor cell (CTC) and tumor-derived extracellular vesicle (tdEV) loads are prognostic factors of survival in patients with carcinoma. The current method of CTC enumeration relies on operator review and,...
9.
Stevens M, Harder P, Terstappen L
Lab Chip
. 2023 Dec;
24(3):460-466.
PMID: 38105678
Immunomagnetic enrichment of cell populations from bodily fluids followed by immunofluorescent labeling is an established sample preparation method often used for the detection and enumeration of rare cells such as...
10.
Stevens M, Mentink A, Coumans F, Dathathri E, Isebia K, Kraan J, et al.
Mol Oncol
. 2023 Dec;
PMID: 38073130
The clinical utility of circulating tumor cells (CTCs) is hampered by the low number of cells detected. Diagnostic leukapheresis (DLA) offers a solution but, due to the observed non-specific binding...